A New Flu Shot Debate: The Promise and the Pitfalls of mRNA
The FDA’s advisory panel gave a 9‑to‑zero nod to Moderna’s mRNA flu vaccine for people aged fifty and older. This decision follows a previous rejection that cited incomplete trials, sparking debate over safety and effectiveness. The panel’s vote hinges on Phase‑4 data showing a 26. 6 % relative boo